[go: up one dir, main page]

PE20210635A1 - Oligonucleotidos inmunoestimulantes - Google Patents

Oligonucleotidos inmunoestimulantes

Info

Publication number
PE20210635A1
PE20210635A1 PE2020000765A PE2020000765A PE20210635A1 PE 20210635 A1 PE20210635 A1 PE 20210635A1 PE 2020000765 A PE2020000765 A PE 2020000765A PE 2020000765 A PE2020000765 A PE 2020000765A PE 20210635 A1 PE20210635 A1 PE 20210635A1
Authority
PE
Peru
Prior art keywords
oligonucleotides
methods
immunostimulanting
immunostimulatory
tlr21
Prior art date
Application number
PE2020000765A
Other languages
English (en)
Inventor
Thoma Ilg
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of PE20210635A1 publication Critical patent/PE20210635A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente se describen oligonucleotidos inmunoestimulantes y composiciones y metodos de uso de estos. Mas especificamente, se describen oligonucleotidos inmunoestimulantes, metodos para optimizar las propiedades inmunoestimulantes de los oligonucleotidos, y metodos para usar los oligonucleotidos inmunoestimulantes para provocar una respuesta inmunitaria mediada por el Receptor Tipo Toll 21 (TLR21)
PE2020000765A 2017-12-15 2018-12-07 Oligonucleotidos inmunoestimulantes PE20210635A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17207740 2017-12-15
EP17207750 2017-12-15
EP17207746 2017-12-15
PCT/EP2018/083958 WO2019115386A1 (en) 2017-12-15 2018-12-07 Immunostimulatory oligonucleotides

Publications (1)

Publication Number Publication Date
PE20210635A1 true PE20210635A1 (es) 2021-03-23

Family

ID=66818991

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2020000765A PE20210635A1 (es) 2017-12-15 2018-12-07 Oligonucleotidos inmunoestimulantes
PE2020000767A PE20200933A1 (es) 2017-12-15 2018-12-07 Composiciones inmunoestimulantes
PE2020000766A PE20210636A1 (es) 2017-12-15 2018-12-07 Oligonucleotidos inmunoestimulantes

Family Applications After (2)

Application Number Title Priority Date Filing Date
PE2020000767A PE20200933A1 (es) 2017-12-15 2018-12-07 Composiciones inmunoestimulantes
PE2020000766A PE20210636A1 (es) 2017-12-15 2018-12-07 Oligonucleotidos inmunoestimulantes

Country Status (23)

Country Link
US (7) US11932857B2 (es)
EP (4) EP3701032A1 (es)
JP (5) JP7458977B2 (es)
KR (4) KR20200098638A (es)
CN (5) CN119656298A (es)
AU (5) AU2018385256B2 (es)
BR (2) BR112020011815A2 (es)
CA (3) CA3085657A1 (es)
CL (3) CL2020001561A1 (es)
CO (3) CO2020007102A2 (es)
CR (1) CR20200260A (es)
DK (1) DK3700564T3 (es)
DO (3) DOP2020000106A (es)
ES (1) ES3052969T3 (es)
IL (3) IL274975A (es)
MX (4) MX2020006244A (es)
PE (3) PE20210635A1 (es)
PH (3) PH12020550906A1 (es)
SG (3) SG11202004471RA (es)
TW (2) TWI821224B (es)
UY (3) UY38014A (es)
WO (3) WO2019115386A1 (es)
ZA (1) ZA202004317B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3993834A1 (en) 2019-07-05 2022-05-11 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
US20230241196A1 (en) * 2020-01-27 2023-08-03 Oregon State University Gonorrhea subunit vaccine
CN113493790A (zh) * 2020-04-01 2021-10-12 南京华普生物技术股份有限公司 具有免疫调节功能的CpG ODN及其应用
EP3892260A1 (en) * 2020-04-10 2021-10-13 Bayer Animal Health GmbH Immunostimulatory compositions based on liposomes with zwiterionic and cationic lipids
WO2022032191A1 (en) 2020-08-07 2022-02-10 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
CN112159814B (zh) * 2020-10-29 2023-05-16 中国农业科学院兰州兽医研究所 一种CpG寡聚脱氧核苷酸及制备与其用途
CN113797329A (zh) * 2021-10-19 2021-12-17 启锰生物科技(江苏)有限公司 一种二价锰佐剂和CpG佐剂的疫苗佐剂组合物及其制作方法
CN116218852A (zh) * 2023-02-22 2023-06-06 中国人民解放军陆军军医大学 一种靶向基因启动子G-四联体区域的sgRNA及其用途
WO2025149000A1 (zh) * 2024-01-09 2025-07-17 康希诺(上海)生物研发有限公司 一种免疫刺激序列截断多聚a尾的序列构建及其应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719028A (en) * 1992-12-07 1998-02-17 Third Wave Technologies Inc. Cleavase fragment length polymorphism
CA2194761C (en) * 1994-07-15 2006-12-19 Arthur M. Krieg Immunomodulatory oligonucleotides
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
CZ301488B6 (cs) 1999-09-25 2010-03-24 University Of Iowa Research Foundation Použití imunostimulacních nukleových kyselin
WO2001022990A2 (en) * 1999-09-27 2001-04-05 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
KR100359753B1 (ko) * 1999-12-21 2002-11-09 주식회사 제넥신 면역조절능력 및 안전성이 증가되고 ｄＧ 연속서열이결합된 포스포다이에스터 ＣｐＧ올리고데옥시뉴클레오티드 변형체
WO2002000926A2 (en) 2000-06-30 2002-01-03 Epigenomics Ag Diagnosis of diseases associated with signal transduction
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
KR101137572B1 (ko) * 2003-06-11 2012-05-30 이데라 파마슈티칼즈, 인코포레이티드 안정화된 면역조절 올리고뉴클레오티드
CA2536139A1 (en) 2003-09-25 2005-04-07 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
US8188254B2 (en) * 2003-10-30 2012-05-29 Coley Pharmaceutical Gmbh C-class oligonucleotide analogs with enhanced immunostimulatory potency
EP1680446B1 (en) * 2003-11-05 2007-10-31 Pevion Biotech Ltd. Compositions comprising melittin-derived peptides and methods for the potentiation of immune responses against target antigens
CN1250737C (zh) * 2003-11-07 2006-04-12 深圳市未来海洋科技发展有限公司 含CpG DNA畜禽疫苗佐剂的PCR制备方法
KR100558851B1 (ko) * 2004-01-08 2006-03-10 학교법인연세대학교 면역조절능력이 증가된 ＣｐＧ 올리고데옥시뉴클레오티드변형체
WO2005115359A2 (en) * 2004-05-06 2005-12-08 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Methods and compositions for the treatment of uveitis
AU2006216493A1 (en) * 2005-02-24 2006-08-31 Coley Pharmaceutical Gmbh Immunostimulatory oligonucleotides
EP1764108A1 (en) * 2005-09-14 2007-03-21 Gunther Hartmann Compositions comprising immunostimulatory RNA oligonucleotides and methods for producing said RNA oligonucleotides
US8114636B2 (en) * 2006-02-10 2012-02-14 Life Technologies Corporation Labeling and detection of nucleic acids
ES2526879T3 (es) 2006-02-15 2015-01-16 Adiutide Pharmaceuticals Gmbh Composiciones y procedimientos para formulaciones de oligonucleótidos
CN100418583C (zh) 2006-02-21 2008-09-17 朱鸿飞 预防和治疗乳腺炎的药物组合物
US20080124366A1 (en) 2006-08-06 2008-05-29 Ohlfest John R Methods and Compositions for Treating Tumors
CN102851295B (zh) * 2006-08-28 2015-01-07 长春华普生物技术有限公司 Toll 样受体调节性寡核苷酸及其用途
MX2009003398A (es) 2006-09-27 2009-08-12 Coley Pharm Gmbh Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
MX2010001014A (es) * 2007-08-13 2010-03-01 Coley Pharm Gmbh Motivos de secuencias de arn en el contexto de uniones de internucleotidos definidas que inducen perfiles inmunomoduladores especificos.
DK2427472T3 (en) 2009-05-05 2016-09-12 Miragen Therapeutics Lipophilic polynukleotidkonjugater
MX336019B (es) 2009-05-14 2016-01-06 Bayer Ip Gmbh Respuesta inmunitaria reforzada en especies aviares.
US10456463B2 (en) 2010-05-28 2019-10-29 Zoetis Belgium S.A Vaccines comprising cholesterol and CpG as sole adjuvant-carrier molecules
CN101979542B (zh) * 2010-10-28 2011-12-28 国家兽用生物制品工程技术研究中心 含CpG基序的核酸序列的制备方法及应用
BR112013016231B1 (pt) 2010-12-22 2021-03-23 Bayer Intellectual Property Gmbh Composição imunomoduladora para o tratamento de doença respiratória bovina
EP2471926A3 (en) * 2010-12-30 2012-07-11 Intervet International BV Immunostimulatory oligodeoxynucleotides
WO2012160183A1 (en) * 2011-05-26 2012-11-29 Intervet International B.V. Immunostimulatory oligodeoxynucleotides
CA2834440A1 (en) * 2011-05-26 2012-11-29 Intervet International B.V. Immunostimulatory oligodeoxynucleotides
ES2731524T3 (es) 2012-04-05 2019-11-15 Massachusetts Inst Technology Composiciones inmunoestimuladoras y métodos de uso de las mismas
AR091569A1 (es) 2012-06-28 2015-02-11 Intervet Int Bv Receptores de tipo toll
EP2922861A4 (en) * 2012-11-26 2016-09-14 Caris Life Sciences Switzerland Holdings Gmbh BIOMARKER COMPOSITIONS AND METHODS
TWI680767B (zh) 2013-05-01 2020-01-01 美商雷格勒斯治療公司 用於增強的細胞攝取之化合物及方法
US20160168571A1 (en) * 2013-07-19 2016-06-16 National Health Research Institutes CpG-OLIGODEOXYNUCLEOTIDE, IMMUNOGENIC COMPOSITION COMPRISING THE SAME, AND METHODS FOR PREPARING THE COMPOSITION AND STIMULATING IMMUNE RESPONSE THEREBY
AR097029A1 (es) * 2013-07-26 2016-02-17 Intervet Int Bv Aceleración de la respuesta inmune inducida por virus vectorial en aves, composición, uso, método para la vacunación y método para acelerar la respuesta inmune
GB2517700A (en) * 2013-08-27 2015-03-04 Lgc Ltd Oligonucleotides comprising a secondary structure and uses thereof
CA2940794C (en) 2014-02-28 2022-05-31 Bayer Animal Health Gmbh Immunostimulatory plasmids
US10888603B2 (en) * 2016-02-12 2021-01-12 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating cancer cells expressing tumor-associated integrins

Also Published As

Publication number Publication date
AU2018382419A1 (en) 2020-06-04
PH12020550906A1 (en) 2021-05-17
US20210062192A1 (en) 2021-03-04
SG11202004773SA (en) 2020-06-29
SG11202004952UA (en) 2020-06-29
CR20200260A (es) 2020-08-01
PH12020550903A1 (en) 2021-05-17
US11932857B2 (en) 2024-03-19
CN120519464A (zh) 2025-08-22
CO2020007120A2 (es) 2020-06-19
US20240076681A1 (en) 2024-03-07
IL275086A (en) 2020-07-30
US20250215439A1 (en) 2025-07-03
EP3694549A1 (en) 2020-08-19
IL274975A (en) 2020-07-30
RU2020122545A3 (es) 2022-05-04
EP3701032A1 (en) 2020-09-02
JP7770769B2 (ja) 2025-11-17
EP4647437A2 (en) 2025-11-12
DOP2020000113A (es) 2020-08-31
JP7760560B2 (ja) 2025-10-27
TW201936923A (zh) 2019-09-16
JP2021506246A (ja) 2021-02-22
JP2023156485A (ja) 2023-10-24
KR20250048594A (ko) 2025-04-09
US12305173B2 (en) 2025-05-20
ES3052969T3 (en) 2026-01-16
AU2025204678A1 (en) 2025-07-17
TW201940192A (zh) 2019-10-16
CO2020007102A2 (es) 2020-06-19
AU2025205082A1 (en) 2025-07-31
BR112020011815A2 (pt) 2020-11-17
RU2020122545A (ru) 2022-01-19
JP7458977B2 (ja) 2024-04-01
KR20200098638A (ko) 2020-08-20
UY38016A (es) 2019-06-28
TWI900461B (zh) 2025-10-11
PE20200933A1 (es) 2020-09-17
MX2020006243A (es) 2020-09-03
AU2018382419B2 (en) 2025-04-10
EP3700564B1 (en) 2025-09-17
JP2021506779A (ja) 2021-02-22
IL275217A (en) 2020-07-30
JP2023153970A (ja) 2023-10-18
CL2020001560A1 (es) 2020-11-06
KR20200099556A (ko) 2020-08-24
AU2018385257A1 (en) 2020-06-18
MX2025007909A (es) 2025-08-01
CA3085657A1 (en) 2019-06-20
DOP2020000106A (es) 2020-08-31
US11542507B2 (en) 2023-01-03
BR112020011838A2 (pt) 2020-11-24
CA3085575A1 (en) 2019-06-20
WO2019115402A1 (en) 2019-06-20
KR102787688B1 (ko) 2025-03-27
DOP2020000107A (es) 2020-08-31
WO2019115385A1 (en) 2019-06-20
CA3085661A1 (en) 2019-06-20
CN111801116B (zh) 2024-11-26
AU2018385257B2 (en) 2025-04-10
CN111801419A (zh) 2020-10-20
CO2020007100A2 (es) 2020-06-19
MX2020006246A (es) 2020-09-03
UY38014A (es) 2019-06-28
KR20200098637A (ko) 2020-08-20
WO2019115386A9 (en) 2020-07-23
US20200385733A1 (en) 2020-12-10
JP7273040B2 (ja) 2023-05-12
US20230332162A1 (en) 2023-10-19
AU2018385256B2 (en) 2025-09-25
CL2020001562A1 (es) 2020-11-06
MX2020006244A (es) 2020-09-03
CL2020001561A1 (es) 2020-11-06
SG11202004471RA (en) 2020-06-29
ZA202004317B (en) 2023-05-31
PE20210636A1 (es) 2021-03-23
CN111447949B (zh) 2025-07-11
WO2019115386A1 (en) 2019-06-20
CN119656298A (zh) 2025-03-21
PH12020550904A1 (en) 2021-05-17
RU2020122553A (ru) 2022-01-17
JP2021506245A (ja) 2021-02-22
US20230174990A1 (en) 2023-06-08
CN111801116A (zh) 2020-10-20
DK3700564T3 (da) 2025-11-10
BR112020011845A2 (pt) 2020-11-24
US20210170020A1 (en) 2021-06-10
TW201936924A (zh) 2019-09-16
CN111447949A (zh) 2020-07-24
TWI821224B (zh) 2023-11-11
EP3700564A1 (en) 2020-09-02
UY38015A (es) 2019-06-28
AU2018385256A1 (en) 2020-06-11

Similar Documents

Publication Publication Date Title
PE20210635A1 (es) Oligonucleotidos inmunoestimulantes
CO2018011804A2 (es) Receptores quiméricos de flt3 y métodos de uso de los mismos
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
MX2024010239A (es) Receptores de antigenos quimericos dirigidos a bcma y metodos de uso de estos.
MX2020012765A (es) Métodos y compuestos de ácido nucleico modificado con lípidos.
MX2018003491A (es) Represores de htt y usos de estos.
UY37564A (es) Aislados de lysinibacillus y usos de los mismos
UY37563A (es) Aislados de bacillus y usos de los mismos
MX2019001672A (es) Composiciones de poxvirus quiméricos y usos de las mismas.
DOP2016000223A (es) Plásmidos inmunoestimuladores
CL2016002148A1 (es) Derivados de fenilen-1,5-diamina 2,4-disustituidos y aplicaciones de los mismos, y composiciones farmacéuticas y composiciones farmacéuticamente aceptables preparadas a partir de los mismos.
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza.
MX2020004600A (es) Constructos de oligonucleotidos y usos de estos.
MX2016014308A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7.
MX382791B (es) Conjugados novedosos de glicano y uso de los mismos
MX2019004690A (es) Constructos de anticuerpos.
CR20160418A (es) Nuevos compuestos biciclicos de 7 eslabones
ECSP21068097A (es) Anticuerpos claudina 6 y usos de los mismos
CO2021000041A2 (es) Degradadores selectivos del receptor de estrógeno
CO2020015747A2 (es) Analogos de rapamicina y usos de los mismos
BR112017005524A2 (pt) segmentos de rna viral como agentes imunomoduladores e componentes de vacina
AR113949A1 (es) Oligonucleótidos inmunoestimulantes
AR124614A1 (es) Oligonucleótidos inmunoestimulantes
TH2001003350A (th) โอลิโกนิวคลีโอไทด์ที่กระตุ้นระบบภูมิคุ้มกัน
CR20200261A (es) Oligonucleótidos inmunoestimulantes